Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 16, 2025MetabolitesOpen Access

SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAna Checa-RosOOOwahabanun-Joshua OkojieLDLuis D’Marco

Discussion

Loading...

Member takes

Overview

Observational analysis reveals sglt2 inhibitors improve heart failure and chronic kidney disease outcomes in patients, indicating a broad metabolic impact.

Key Points

  • SGLT2 inhibitors demonstrate significant reductions in heart failure hospitalizations and chronic kidney disease progression, enhancing patient outcomes.
  • Landmark trials confirm robust benefits of SGLT2 inhibitors, showing reductions in cardiovascular mortality and improved metabolic health.
  • Assessment of systemic effects highlights the role of SGLT2 inhibitors in modulating inflammation and glucose reabsorption mechanisms.
  • This therapeutic class may expand to address conditions like non-alcoholic fatty liver disease, raising potential implications for metabolic syndrome.

Cite This Study

Checa-Ros et al. (2025) studied this question.

synapsesocial.com/papers/68c23626b210217d64773322https://doi.org/10.3390/metabo15080536
View Full Paper
Ask AI
Bookmark
Share